产品中心Cell Resources
联系我们CONTACT US
400-999-210024小时服务热线
产品概述
| 名称 | HuCC-T1 (人胆管癌细胞) (STR鉴定正确) |
| 别称 | HuCCT-1; HUCCT-1; HUCC-T1; HUCCT1; HuCCT1 |
| 种属 | 人 |
| 生长特性 | 贴壁细胞 |
| 细胞形态 | 上皮细胞样 |
| 冻存条件 | 冻存液：55% 基础培养基+40%FBS+5%DMSO 温度：液氮 |
| 培养方案A（默认） |
培养条件:
气相：空气，95%；CO2，5%, 温度：37℃
|
| 推荐传代比例 | 1:2 |
| 推荐换液频率 | 2-3次/周 |
| 年龄（性别） | 男性；56岁 |
| 组织来源 | 胆管，腹水转移 |
| 细胞类型 | 肿瘤细胞 |
| 肿瘤类型 | 肝胆癌细胞 |
| 生物安全等级 | BSL-1 |
| 倍增时间 | ~55 hours |
| 保藏机构 | JCRB; JCRB0425 RCB; RCB1960 TKG; TKG 0389 |
STR鉴定
-
STR位点信息
Amelogenin X,Y CSF1PO 11,12 D2S1338 17,18 D3S1358 15 D5S818 12,13 D7S820 10,11 D8S1179 10 D13S317 11,13 D16S539 11,12 D18S51 13 D19S433 13 D21S11 31 FGA 20,23 PentaD 10 PentaE 15,18 TH01 7,10 TPOX 8 vWA 18 D6S1043 13 D12S391 18,20 D2S441 10,11 -
STR鉴定图
-
参考文献
-
Protein regulator of cytokinesis 1 accentuates cholangiocarcinoma progression via mTORC1-mediated glycolysis (2024-02-28)
作者：Chao Zhang:1.Department of Hepatobiliary Surgery, Shandong Provincial Hospital, Shandong University, 324 Jingwuwei 7Th Road, Jinan, 250021, Shandong, People's Republic of China. ; 2.Department of Hepatobiliary Surgery, Linyi People's Hospital, Linyi, 276034, Shandong, People's Republic of China. ; Chengkun Qin:1.Department of Hepatobiliary Surgery, Shandong Provincial Hospital, Shandong University, 324 Jingwuwei 7Th Road, Jinan, 250021, Shandong, People's Republic of China. qinchengkun_slyy@163.com. ;
期刊：Protein regulator of cytokinesis 1 accentuates cholangiocarcinoma progression via mTORC1-mediated glycolysis
DOI：10.1007/s13577-024-01032-7
影响因子 ：4.3
引用产品： HCCC-9810 细胞 , HuCC-T1 细胞 , RBE 细胞
-
Development of potent antibody drug conjugates against ICAM1+ cancer cells in preclinical models of cholangiocarcinoma (2023-09-16)
作者：Bing Zhu:1.Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, Zhejiang, 310022, China. ; 2.Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, Zhejiang, 310018, China. ; Xinyan Wang:1.Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, Zhejiang, 310022, China. ; 2.Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, Zhejiang, 310018, China. ; 3.Institute of Molecular Medicine, Hangzhou Institute for Advanced Study (UCAS), Hangzhou, Zhejiang, 310000, China. ; Takaya Shimura:1.Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, Nagoya, 467-8601, Japan. ; Andrew C Huang:1.MabPlex International, Yantai, Shandong, 264006, China. ; Nana Kong:1.MabPlex International, Yantai, Shandong, 264006, China. ; Yujie Dai:1.MabPlex International, Yantai, Shandong, 264006, China
期刊：Development of potent antibody drug conjugates against ICAM1+ cancer cells in preclinical models of cholangiocarcinoma
DOI：10.1038/s41698-023-00447-z
影响因子 ：7.9
引用产品： HuCC-T1 细胞 , HCCC-9810 细胞
-
Identification of SPRYD4 as a tumour suppressor predicts prognosis and correlates with immune infiltration in cholangiocarcinoma (2023-05-04)
作者：Zuyi Ma:1.Department of General Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, No. 1 Shuaifuyuan, Dongcheng District, Beijing, 100005, China. ; Tiange Xie:1.Department of General Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, No. 1 Shuaifuyuan, Dongcheng District, Beijing, 100005, China. ; Jia Sun:1.Department of General Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, No. 1 Shuaifuyuan, Dongcheng District, Beijing, 100005, China. ; Jianchun Yu:1.Department of General Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science a
期刊：Identification of SPRYD4 as a tumour suppressor predicts prognosis and correlates with immune infiltration in cholangiocarcinoma
DOI：10.1186/s12885-023-10810-9
影响因子 ：3.8
引用产品： HuCC-T1 细胞 , RBE 细胞 , CCLP-1 细胞 , huh28 细胞 , QBC939 细胞 , HCCC-9810 细胞
-
Hsa_circ_0019054 up-regulates HIF1A through sequestering miR-340–5p to promote the tumorigenesis of intrahepatic cholangiocarcinoma (2022-12-06)
作者：Jintian Tang:1.Department of Hepatopancreatobiliary, Cancer Hospital Affiliated to Xinjiang Medical University, Urumqi, China. ; Runjuan Tang:1.Rehabilitation Department, The Second Affiliated Hospital of Xinjiang Medical University, Urumqi, China. ; Peng Gu:1.Interventional Department, Cancer Hospital Affiliated to Xinjiang Medical University, Urumqi, China. ; Jing Han:1.Office of Drug Clinical Trial Institutions, Cancer Hospital Affiliated to Xinjiang Medical University, Urumqi, China. ; Wukui Huang:1.Interventional Department, Cancer Hospital Affiliated to Xinjiang Medical University, Urumqi, China. ; Feng Xue:1.Department of Hepatopancreatobiliary, Cancer Hospital Affiliated to Xinjiang Medical University, Urumqi, China. ;
期刊：Hsa_circ_0019054 up-regulates HIF1A through sequestering miR-340–5p to promote the tumorigenesis of intrahepatic cholangiocarcinoma
影响因子 ：3.2
引用产品： 人肝内胆管上皮细胞 , RBE 细胞 , HuCC-T1 细胞
FAQs
Q：{{item.question}}
A：
产品资料
识别码示意图
![HUV-EC-C [HUVEC] (人脐静脉血管内皮细胞) (STR鉴定正确)(暂不出售）](/Public/upfile/pic/xbx/CL-0122-1.jpg)
